Učitavanje...
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully. Next to monoclonal anti-HER2 antibodies and tyrosi...
Spremljeno u:
| Izdano u: | Int J Mol Sci |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6429068/ https://ncbi.nlm.nih.gov/pubmed/30841523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20051115 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|